




Supplementary Figure 4. Treatment heterogeneity by CKD status for all outcomes for comparison of ARB vs ACEi.

CKD: estimated GFR <60 mL/min/1.73m²; ESKD: end-stage kidney disease. n (%)= number of events (percent). P-value is the test of interaction between the treatment for each outcome. Analysis is propensity-score — weighted with robust standard errors. Analysis adjusted for time since first eligible period. Loss of GFR or ESKD defined as: 50% reduction in estimated glomerular filtration rate (eGFR), start of kidney replacement therapy (KRT) or eGFR<15. ESKD defined as: start of KRT or eGFR<15. Kidney outcomes only include those subjects who have an eGFR measurement before start of the eligible period but within 6 months and also adjusted for baseline serum creatinine.